Inhaled hope for scarred lungs: trial tests new therapy
NCT ID NCT07181382
Summary
This study is testing an inhaled medication called seralutinib for people with high blood pressure in the lungs caused by scarring from another lung disease. The main goal is to see if the drug can help people walk farther in six minutes after 24 weeks of treatment. The trial will also monitor long-term safety for up to three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hillel Yaffe Medical Center
Hadera, Israel
-
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia, 23230, United States
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131, United States
-
Valley Advanced Lung Diseases Institute
Fresno, California, 93720, United States
Conditions
Explore the condition pages connected to this study.